Safety of RhD alloimmunization
10.13303/j.cjbt.issn.1004-549x.2021.05.012
- VernacularTitle:RhD主动免疫安全性研究
- Author:
Chenyue LI
1
;
Sitian CHEN
2
;
Rui HE
1
;
Ning SONG
1
;
Li TIAN
1
;
Jinjin ZHANG
3
;
Yongli HUANG
3
;
Yanchao XING
3
;
Zhong LIU
1
Author Information
1. Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Transfusion Adverse Reactionsof Chinese Academy of Medical Sciences, Chengdu 610052, China
2. Hunan Children's Hospital
3. General Hospital of Xinjiang Military Region
- Publication Type:Journal Article
- Keywords:
RhD negative;
RhD positive red blood cell transfusion;
alloimmunization;
anti-D immunoglobulin;
haemolytic disease of the fetus and newborn(HDFN);
blood safety
- From:
Chinese Journal of Blood Transfusion
2021;34(5):489-493
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To explore the safety of RhD-positive red blood cells (RBCs) immunization schedules in RhD-negative volunteers, so as to facilitate the development of domestic anti-D immunoglobulin. 【Methods】 From January 2018 to April 2020, 23 RhD negative volunteers with informed consent were enrolled and divided into initial immunization group and booster immunization group. The initial immunization included first immunization, second immunization and third immunization. Four groups, i. e. 3 cases of 20 mL, 8 of 30 mL, 6 of 40 mL, and 6 of 50 mL, were involved in initial immunization. After the initial immunization response, booster immunizations were performed every 3 months. According to the anti-D titer before each immunization, the booster immunization doses were set to 0.5, 1 and 2 mL. Whole blood samples of 5mL/ person (time) were collected 24 h and 1 week after each infusion, and the blood routine, liver, kidney and blood coagulation function and anti-D titer were detected. The differences of detection (index) values at 24 h and 1 week after the first immunization and booster immunization in each (dose) group were compared. 【Results】 No statistically significant differences were observed in hemolysis index values (all within the range of medical reference values) 24 h or 1 week after initial immunization among RhD positive RBCs of 20, 30, 40 and 50mL(P>0.05). The differences between the hemolysis index values and the basic values before the immune response (all within the range of medical reference values) after 0.5 or 1 mL booster immunizations were also not statistically different (P>0.05). However, the differences (μmol/L)between total bilirubin levels and the basic values before the immune response (1.55±1.87, 6.29±2.66) were significantly different after 2 mL booster immunization (P<0.05). 【Conclusion】 No risks affecting the safety of RhD negative volunteers was found in the immunization schedule proposed in this study.
